Tian Q, Zeng H, Lu QQ, Xie HY, Li Y. Diagnostic value of serum vascular endothelial growth factor and interleukin-17 in primary hepatocellular carcinoma. World J Gastrointest Surg 2024; 16(9): 2934-2941 [DOI: 10.4240/wjgs.v16.i9.2934]
Corresponding Author of This Article
Yong Li, MMed, Doctor, Department of Oncology Hematology, Hanyang Hospital Affiliated to Wuhan University of Science and Technology, No. 53 Mohu Road, Hanyang District, Wuhan 430050, Hubei Province, China. yongliandy@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2934-2941 Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2934
Diagnostic value of serum vascular endothelial growth factor and interleukin-17 in primary hepatocellular carcinoma
Qi Tian, Hui Zeng, Qi-Quan Lu, Hai-Ying Xie, Yong Li
Qi Tian, Qi-Quan Lu, Hai-Ying Xie, Clinical Laboratory, Hanyang Hospital Affiliated to Wuhan University of Science and Technology/Wuhan Hanyang Hospital, Wuhan 430050, Hubei Province, China
Yong Li, Department of Oncology Hematology, Hanyang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430050, Hubei Province, China
Author contributions: Tian Q contributed to the conception and design; Tian Q, Zeng H and Xie HY contributed to the analysis and interpretation of data; Tian Q and Li Y contributed to the writing, review, and/or revision of the manuscript; all authors contributed to the acquisition of data (acquired and managed patients) and final approved the manuscript.
Institutional review board statement: This study was approved by the Ethic Committee of Hanyang Hospital Affiliated to Wuhan University of Science and Technology.
Informed consent statement: As the study used anonymous and pre-existing data, the requirement for the informed consent from patients was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong Li, MMed, Doctor, Department of Oncology Hematology, Hanyang Hospital Affiliated to Wuhan University of Science and Technology, No. 53 Mohu Road, Hanyang District, Wuhan 430050, Hubei Province, China. yongliandy@163.com
Received: July 24, 2024 Revised: August 20, 2024 Accepted: August 21, 2024 Published online: September 27, 2024 Processing time: 55 Days and 14.3 Hours
Core Tip
Core Tip: The incidence and mortality rates of primary hepatocellular carcinoma (PHC) have been increasing. Despite significant advancements in medical care, improving treatment outcomes and prognosis for liver cancer remains a global challenge. This study measured the levels of vascular endothelial growth factor (VEGF) and interleukin (IL)-17 in the serum of PHC patients using Enzyme-Linked Immunosorbent Assay, with healthy individuals as controls. This study aimed to assess changes in serum VEGF and IL-17 levels and evaluate their diagnostic efficacy for PHC while exploring their correlations with patients’ clinicopathological characteristics. Our findings confirm that VEGF and IL-17 can serve as valuable reference indicators for the early diagnosis and treatment guidance of PHC, offering crucial insights for enhancing early management strategies.
